It appears from several retrospective individual studies that patients with metastases limited to bone35,46, HER2-positive disease31,43,54,55, favourable response to primary systemic therapy, and a resectable primary tumour are most likely to derive significant survival benefit from LRT. This evidence concerns the gene ERBB2 and neoplasm.